von Stein Philipp, Seitz Lukas, Wienemann Hendrik, Hohmann Christopher, Baar Till, Baldus Stephan, Halbach Marcel
Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Faculty of Medicine, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.
Front Cardiovasc Med. 2023 Dec 13;10:1265452. doi: 10.3389/fcvm.2023.1265452. eCollection 2023.
Previous trials investigating antithrombotic therapy with a direct oral anticoagulant (DOAC) and a P2Y12 inhibitor after percutaneous coronary intervention (PCI), termed dual therapy, allowed a short period of triple therapy including a DOAC, a P2Y12 inhibitor, and aspirin.
This study aimed to determine whether discontinuation of aspirin on the first post-procedural day is safe or causes ischemic events.
Ischemic and bleeding events during hospitalization were investigated retrospectively in all patients treated with dual therapy (DOAC + P2Y inhibitor, designated as group 1) or triple therapy (DOAC + P2Y inhibitor+aspirin, designated as group 2) from day 1 after PCI at our center.
Of 4,564 consecutive PCI procedures, 1,059 (23.2%) had an indication for OAC. Of these, 322 met the inclusion criteria for group 1 and 62 for group 2. Baseline characteristics, CHADS-VASc and HAS-BLED scores showed no relevant differences between the two groups, and the main indication for DOAC therapy was atrial fibrillation in both groups. Approximately ¼ of patients were treated for acute coronary syndrome. The mean length of post-procedural hospitalization was 2.1 ± 2.5 and 2.2 ± 3.0 days in group 1 and 2, respectively ( = 0.305). One patient per group suffered a TIA ( = 0.297). There were no other ischemic events and no statistically significant differences in bleeding events. A subgroup analysis of cases hospitalized for ≥2 post-procedural days (group 1: 100 cases, mean 4.4 ± 3.4 days vs. group 2: 25 cases, mean 4.0 ± 4.1 days) confirmed these results.
The initiation of dual therapy and thus discontinuation of aspirin on the first postprocedural day appears to be safe with respect to short-term ischemic events in a real-world population. Almost ¼ of patients undergoing PCI have an indication for OAC, highlighting the relevance of this issue.
先前关于经皮冠状动脉介入治疗(PCI)后使用直接口服抗凝剂(DOAC)和P2Y12抑制剂进行抗血栓治疗(称为双联疗法)的试验允许在短时间内进行三联疗法,包括一种DOAC、一种P2Y12抑制剂和阿司匹林。
本研究旨在确定术后第一天停用阿司匹林是否安全或会引发缺血性事件。
回顾性调查了在我们中心接受PCI术后第1天开始接受双联疗法(DOAC + P2Y抑制剂,指定为第1组)或三联疗法(DOAC + P2Y抑制剂+阿司匹林,指定为第2组)治疗的所有患者住院期间的缺血性和出血性事件。
在4564例连续的PCI手术中,1059例(23.2%)有口服抗凝剂(OAC)指征。其中,322例符合第1组纳入标准,62例符合第2组纳入标准。两组的基线特征、CHADS-VASc和HAS-BLED评分无显著差异,两组DOAC治疗的主要指征均为房颤。约四分之一的患者因急性冠状动脉综合征接受治疗。第1组和第2组术后住院平均时长分别为2.1±2.5天和2.2±3.0天(P = 0.305)。每组各有1例患者发生短暂性脑缺血发作(TIA)(P = 0.297)。无其他缺血性事件,出血事件也无统计学显著差异。对术后住院≥2天的病例进行亚组分析(第1组:100例,平均4.4±3.4天;第2组:25例,平均4.0±4.1天)证实了这些结果。
对于现实世界中的人群,在术后第一天开始双联疗法并停用阿司匹林在短期缺血性事件方面似乎是安全的。几乎四分之一接受PCI的患者有OAC指征,凸显了该问题的相关性。